This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
NORCROSS, Ga., May 29, 2014 (GLOBE NEWSWIRE) --
Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company will present at the Jefferies 2014 Global Healthcare Conference, to be held June 2-5, 2014, in New York, NY. Dr. Harold H. Shlevin, Chief Operating Officer and Corporate Secretary of Galectin Therapeutics, will provide an overview of the Company's business and recent and upcoming milestones during his live presentation.
The Jefferies Global Healthcare Conference features an extensive range of public and private healthcare companies across the biopharmaceuticals, life sciences, healthcare services, healthcare information technology and medical technology sectors. Leading executives, institutional investors, private equity investors and venture capital firms will address near- and long-term investment opportunities and discuss the driving forces in the healthcare industry.
WHAT: Galectin Therapeutics presentation at Jefferies 2014 Global Healthcare Conference WHO: Presentation by Dr. Harold Shlevin, Chief Operating Officer, Galectin Therapeutics WHEN: Monday, June 2, 2014, 11 a.m. Eastern Daylight Time
Dr. Shlevin's presentation will be webcast live at
http://wsw.com/webcast/jeff82/galt/. The archived webcast will be available for 90 days following the presentation.
For more information on the Jefferies 2014 Global Healthcare Conference, please visit
http://www.jefferies.com/OurFirm/Conferences/325/148About Galectin Therapeutics
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at
CONTACT: Galectin Therapeutics Inc.
Dr. Harold H. Shlevin (678)-615-3213
Chief Operating Officer